Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

2.

Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia

3.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire

4.

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot